Alligator Bioscience AB (ATORX) — Cash Flow-to-Debt Ratio
Alligator Bioscience AB (ATORX) has a Cash Flow-to-Debt Ratio of -0.25x as of December 2025, meaning its operating cash flow of Skr-26.00 Million could theoretically repay 0% of its total liabilities (Skr103.74 Million) in one year. Explore Alligator Bioscience AB (ATORX) investment intensity to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Alligator Bioscience AB Cash Flow-to-Debt Ratio (2011–2025)
Historical debt coverage capacity for Alligator Bioscience AB across 13 annual periods. Also explore ATORX total asset value for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Alligator Bioscience AB (2011–2025)
Year-by-year debt coverage analysis for Alligator Bioscience AB. For market capitalisation and broader financial context, see ATORX market cap overview.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.50x | Skr-155.99 Million | Skr103.74 Million | ▼ -66.3% |
| 2024 | -0.90x | Skr-212.43 Million | Skr234.93 Million | ▲ +49.1% |
| 2023 | -1.78x | Skr-189.28 Million | Skr106.59 Million | ▲ +17.1% |
| 2022 | -2.14x | Skr-172.61 Million | Skr80.53 Million | ▲ +14.1% |
| 2021 | -2.49x | Skr-127.03 Million | Skr50.93 Million | ▲ +35.2% |
| 2020 | -3.85x | Skr-141.35 Million | Skr36.69 Million | ▼ -13.3% |
| 2019 | -3.40x | Skr-178.96 Million | Skr52.63 Million | ▼ -30.1% |
| 2018 | -2.61x | Skr-104.11 Million | Skr39.85 Million | ▲ +34.2% |
| 2017 | -3.97x | Skr-99.63 Million | Skr25.08 Million | ▼ -159.8% |
| 2016 | -1.53x | Skr-37.61 Million | Skr24.59 Million | ▼ -114.4% |
| 2015 | 10.62x | Skr204.89 Million | Skr19.29 Million | ▲ +595.7% |
| 2014 | -2.14x | Skr-62.74 Million | Skr29.27 Million | ▲ +43.8% |
| 2011 | -3.82x | Skr-34.77 Million | Skr9.11 Million | — |